Market open

Assertio/$ASRT

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Assertio

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Ticker

$ASRT

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Lake Forest, United States

Employees

Website

www.assertiotx.com

Assertio Metrics

BasicAdvanced

$76M

-

-$0.72

0.76 -

Price and volume

Market cap

$76M

Beta

0.76

52-week high

$1.80

52-week low

$0.73

Average daily volume

821K

Financial strength

Current ratio

2.011

Quick ratio

1.482

Long term debt to equity

30.664

Total debt to equity

31.051

Interest coverage (TTM)

-5.93%

Management effectiveness

Return on assets (TTM)

-3.42%

Return on equity (TTM)

-42.36%

Valuation

Price to revenue (TTM)

0.603

Price to book

0.58

Price to tangible book (TTM)

1.98

Price to free cash flow (TTM)

3.728

Growth

Revenue change (TTM)

-25.77%

Earnings per share change (TTM)

-76.91%

3-year revenue growth (CAGR)

4.67%

3-year earnings per share growth (CAGR)

-1.98%

What the Analysts think about Assertio

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Assertio stock.

Assertio Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Assertio Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Assertio News

AllArticlesVideos

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewsWire·2 weeks ago

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

GlobeNewsWire·4 weeks ago

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ASRT

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Assertio stock?

Assertio (ASRT) has a market cap of $76M as of January 15, 2025.

What is the P/E ratio for Assertio stock?

The price to earnings (P/E) ratio for Assertio (ASRT) stock is 0 as of January 15, 2025.

Does Assertio stock pay dividends?

No, Assertio (ASRT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Assertio dividend payment date?

Assertio (ASRT) stock does not pay dividends to its shareholders.

What is the beta indicator for Assertio?

Assertio (ASRT) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.